Organization Overview
The principal purpose of the Fibrolamellar Cancer Foundation (FCF) is to encourage, drive and fund research that will substantially improve outcomes for patients with fibrolamellar carcinoma (FLC), a rare liver cancer that primarily affects adolescents and young adults who have no history of liver disease. Given the urgent need for clinically proven therapies and FLC’s status as an ultra-rare disease, our mission is three-fold: (1) find a cure and effective treatment options for FLC; (2) connect and support the fibrolamellar community; and (3) raise awareness of this disease.
The Foundation was founded in 2009 by Tucker Davis, a 27-year-old patient who lost an 18-month battle with this cancer. Prior to the founding of FCF, fibrolamellar carcinoma received minimal research attention. Since then, FCF-funded research has included a broad range of basic, translational and clinical studies. As the leading non-governmental funder of FLC research, we actively foster collaboration among researchers, clinicians, the pharmaceutical industry, patients and caregivers to support the dream of conquering FLC.
